Cerbios-Pharma brings latest ADC advances to BIO 2019 in Philadelphia
Press Release | Cerbios-Pharma SA
MAY 21, 2019
Lugano, Switzerland: – Cerbios-Pharma SA (Cerbios) will reveal its latest advances in novel antibody drug conjugate (ADC) cGMP production services when it attends the upcoming 26th BIO International Convention in Philadelphia.
Cerbios will exhibit at the at Booth 3109 of the Pennsylvania Convention Center, along with AGC Biologics and Oncotec Biopharma, as part of the PROVEOTM alliance for integrated ADC supply chains.
CDMO development and cGMP manufacturing
Cerbios will present its latest CDMO development and cGMP manufacturing services for ADCs, recombinant proteins and Highly Potent APIs (HPAPIs).
As a regular attendee at BIO International, Cerbios will also present at the event to strengthen its links with its important North American customer base.
Business Development Manager, Dr. Matteo Piazza, will be Cerbios representative in Philadelphia.
Compressed ADC overall development time
“We will be seeking face to face meetings throughout the three days of the conference, particularly with start-ups and mid-size pharma companies in the fields of oncology, highly potent compounds and ADCs,” said Dr. Piazza.
“We will present our highly attractive dedicated panel for ADCs, including our state-of-the-art cGMP conjugation facility, compressed development time, integrated services and significant expertise in the field,” he added.
“Our most convincing promotional offer is the tailored and dedicated services we provide to all our customers,” said Dr. Piazza.
Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacturing of both chemical and biological APIs for its partners world-wide.
Cerbios’ is a global leading supplier of a portfolio of Generic APIs primarily used in Oncology, as well as in the treatment Respiratory and Dermatological disorders.
Exclusive CDMO services are offered for the development and manufacturing of high potency active ingredients (HPAIs) as well as for biological products including monoclonal antibodies, recombinant proteins, antibody drug conjugates (ADCs) and pharma probiotics.
Cerbios provides full CMC support, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs, with paramount ability to supply all technical documentation and support necessary for successful registration. Cerbios’ commercial products are marketed worldwide, primarily in Europe, USA, Japan and India.
Since 2015, Cerbios has been a member of the ADC manufacture PROVEO™ consortium, forged with AGC Biologics of Denmark and with Germany’s Oncotec.
PROVEO can offer an ADCs end-to-end service from substance development through manufacturing to fill & finish.
About BIO International 2019
The 26th Anniversary BIO International Convention (BIO 2019) provides a week of intensive networking for biotechnology and pharma leaders to discover new opportunities and promising partnerships. It attracts more than 16,000 delegates involved in a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.
BIO International 2019 moves to Philadelphia PA as a four -day event opening June 3 at the Pennsylvania Convention Center. The convention will feature more than 47,000 face-to-face meetings for some 7,000 companies organised using the proprietary BIO One-on-One partnering™ system, as well as hundreds of individual company presentations, a program of world-renowned keynote speakers and some 20 Session Tracks.
A co-located trade show will feature more than 1,800 exhibitors from fields ranging from digital health and diagnostics to bioprocesses.
The event is organized by the Washington DC-based Biotechnology Innovation Organization with more information at: http://convention.bio.org/.
Chiara Brusadelli, Commercial Operations Specialist, Cerbios-Pharma SA
Tel: +41 91 9856311